Nasdaq GlobeNewswire

Apricus Biosciences to Present at the 28th Annual ROTH Conference

Del

SAN DIEGO, 2016-03-08 13:00 CET (GLOBE NEWSWIRE) --

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Barbara Troupin, M.D., Chief Medical Officer, will present at the 28th Annual ROTH Conference on Tuesday, March 15, 2016, at 7:30 a.m. Pacific Time.  The conference will be held at The Ritz Carlton, Dana Point, CA.  Dr. Troupin will provide an update on Vitaros®*, the Company's topical treatment for erectile dysfunction, as well as Apricus' drug candidates fispemifene, for the treatment of men with secondary hypogonadism and RayVa™, for the treatment of patients with Raynaud's phenomenon.

A live audio webcast of the presentation can be accessed via the Investor Relations section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions.  Apricus has completed a Phase 2a trial for RayVa, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon, and plans to conduct additional clinical trials in patients with Raynaud’s phenomenon secondary to scleroderma. Apricus’ lead commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV.  Apricus’ second-generation room temperature Vitaros is currently under development.

For further information on Apricus, visit http://www.apricusbio.com.

*Vitaros® is a registered trademark of NexMed International Limited.  Such trademark is registered in certain countries throughout the world and pending registration in the United States.

         CONTACT: Institutional / Retail Investors: Matthew Beck
         mbeck@troutgroup.com
         The Trout Group LLC
         (646) 378-2933

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Partnership With FAST Technologies Expands Aptean's European Footprint17.1.2018 21:00Pressemelding

ALPHARETTA, Ga., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Aptean, a leading global provider of mission-critical enterprise software solutions, has formed a strategic partnership with FAST Technologies in Northern Ireland. This partnership is an important part of Aptean's growth strategy in the European market, specifically the United Kingdom and the Republic of Ireland. FAST Technologies will sell and support one of Aptean's industry-leading process solutions, Factory Manufacturing Execution System (MES). Process manufacturers use Factory MES to gain real-time visibility into production, operations and quality compliance by adopting a true paperless solution. FAST, a leading provider of industrial automation solutions, is well-established with high-volume manufacturers of retail packaged goods and pharmaceutical products. "We are excited to announce this partnership with Aptean. For many years, we have struggled with an appropriate solution that gives our customers an out-of-the-box experienc

Egyptian Steel recognised in the World Finance 100 guide for 201717.1.2018 15:29Pressemelding

LONDON, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Egyptian Steel currently stands as one of the most powerful companies in Egypt. Its prosperity is largely down to the work of founder and CEO, Ahmed Abou Hashima, whose optimistic and bold approach has seen the company go from strength to strength - even in tough conditions. In spite of Egypt's 2011 revolution, which pushed the country through much turmoil, Egyptian Steel was able to take off, having been founded just the year before. Abou Hashima believes that investors shouldn't be put off in times of political uncertainty and economic upheaval. If they are brave, the rewards can be great. And if his organisation's performance is anything to go by, it seems these are wise words; Egyptian Steel's four steel plants now produce 2.3 million tonnes of steel annually. For its outstanding work, Egyptian Steel has been recognised by World Finance in the magazine's World Finance 100 guide, which identifies the world's strongest organisations. Here, co

Investing in Berlin's thriving real estate market17.1.2018 15:05Pressemelding

LONDON , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Germany's capital Berlin may be well known as a vibrant tourist destination - the city welcomed 12.7 million visitors last year - but it also offers fantastic investment opportunities. Currently, the real estate market is flourishing, but it is also constantly changing. As such, investors will find that a little market knowledge goes a long way. In 2018, the trend towards renting out furnished apartments looks set to continue, with renovated properties achieving a high sell-on value. Locations will also remain a key factor in determining property prices. In Berlin, real estate buyers will find that high-demand areas like Mitte, Prenzlauer Berg and Friedrichshain offer solid opportunities for return on investment (ROI). Alongside Berlin, other cities in former-East Germany are proving increasingly enticing to real estate developers. Leipzig, for example, has a thriving student population and good job prospects as a result of investment from Por

Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar17.1.2018 14:12Pressemelding

SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will host a webinar on Thursday, January 18, 2018 at 10 am EST (3pm BST/UK), presented by renowned immunologist, Dr. Jayant Thatte. Dr. Thatte will review currently available humanized models and describe innovative applications for preclinical immuno-oncology research. The evaluation of immunotherapeutics is hindered by a lack of preclinical oncology models that exhibit functional human immunity. To overcome this obstacle, Crown Bioscience uses cutting-edge humanization protocols to develop innovative research solutions with reconstituted, functional human immune components. These humanized models can be combined with human cancer cell lines or patient-derived xenograft (PDX) mo

Colliers Launches Real Estate Technology Accelerator With Techstars17.1.2018 13:30Pressemelding

Partnership with Global Technology Investor and Accelerator Leader Highlights Commitment to Real Estate Industry Innovation TORONTO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ:CIGI) and (TSX:CIGI), a global leader in commercial real estate services, today announced the launch of the Colliers Proptech Accelerator powered by Techstars. "Disruptive changes in technology, evolving demographics, fierce global competition and increased connectivity are factors impacting all industries," said Dylan Taylor, Colliers President & COO. "And the commercial real estate industry is no exception. Colliers sees this as an opportunity and is committed to being the most enterprising company in our industry by developing innovative and value enhancing services for our clients and professionals. Partnering with Techstars allows us to harness the best and brightest in operating technology accelerators and selectively evaluate and invest in new technologies. The new Colliers

BnkToTheFuture Raises Initial $30 Million for Tokenized Securities Market and Due Diligence Platform17.1.2018 13:15Pressemelding

Largest Online Investment Platform for Fintech, Bitcoin, and Blockchain Ventures to Distribute BnkToTheFuture Token (BFT) for Equity-Backed Token Deals to Accredited Investors GEORGE TOWN, Cayman Islands, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Financial technology investment platform BnkToTheFuture (www.bnktothefuture.com) has raised an initial $30 million for its tokenized equity market and due diligence platform within the first 24 hours of of its token pre-sale open solely to institutional investors and members of its platform. BnkToTheFuture offers the largest online investment platform for investing in the equity of FinTech, Bitcoin, and Blockchain companies as well as Initial Coin Offerings (ICOs) that have passed a stringent due-diligence and compliance process. Already popular as an online investment platform with almost 50,000 professional and accredited investors with over $260 million invested in the funding rounds of FinTech, Bitcoin, and blockchain deals listed on its platform

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom